Equities research analysts at StockNews.com assumed coverage on shares of Zevra Therapeutics (NASDAQ:KMPH – Get Rating) in a research report issued to clients and investors on Thursday. The firm set a "hold" rating on the specialty pharmaceutical company's stock.
KMPH has been the subject of a number of other research reports. Canaccord Genuity Group dropped their target price on Zevra Therapeutics from $20.00 to $19.00 in a report on Thursday, November 10th. Cantor Fitzgerald initiated coverage on Zevra Therapeutics in a report on Thursday, November 17th. They issued an "overweight" rating and a $20.00 target price for the company. One analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $17.25.
Get
Zevra Therapeutics alerts:
Zevra Therapeutics Price Performance
The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.10 and a current ratio of 10.10. Zevra Therapeutics has a 12 month low of $4.00 and a 12 month high of $6.92. The business has a 50-day moving average price of $5.34 and a 200 day moving average price of $5.37.
Insider Transactions at Zevra Therapeutics
In related news, CEO Richard W. Pascoe bought 9,500 shares of the stock in a transaction dated Friday, January 13th. The shares were purchased at an average price of $5.44 per share, for a total transaction of $51,680.00. Following the completion of the purchase, the chief executive officer now directly owns 19,973 shares of the company's stock, valued at $108,653.12. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 1.10% of the company's stock.
Hedge Funds Weigh In On Zevra Therapeutics
A number of hedge funds have recently made changes to their positions in the company. UBS Group AG acquired a new stake in shares of Zevra Therapeutics in the second quarter valued at approximately $26,000. Verition Fund Management LLC acquired a new stake in shares of Zevra Therapeutics in the fourth quarter valued at approximately $46,000. Invesco Ltd. acquired a new stake in shares of Zevra Therapeutics in the first quarter valued at approximately $51,000. Kingsview Wealth Management LLC acquired a new stake in shares of Zevra Therapeutics in the second quarter valued at approximately $54,000. Finally, HRT Financial LP acquired a new stake in shares of Zevra Therapeutics in the fourth quarter valued at approximately $66,000. Institutional investors and hedge funds own 19.39% of the company's stock.
Zevra Therapeutics Company Profile
(Get Rating)
KemPharm, Inc is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy.
Recommended Stories
- Get a free copy of the StockNews.com research report on Zevra Therapeutics (KMPH)
- Fossil Group: Should You Bet On Consumer Discretionary In 2023?
- BJ's Wholesale Club Stock Moves Higher After Strong Results
- Monthly Realty Income is About to Get Bigger
- 3 Large Cap Dividend Challengers for Millennial Investors
- Sea Ltd Is On The Verge Of A 100% Rally, Should You Buy?
Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
